Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug

This article was originally published on Nasdaq

Shares of Syros Pharmaceuticals SYRS were up almost 5% during market hours on Sep 13 after the company announced that its pipeline candidate SY-5609 was granted Orphan Drug designation by the FDA to treat pancreatic cancer.

Responses